Project Grant CLSS00000086238

The University of Pittsburgh is receiving a $488,334 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to implement and evaluate a shared decision-making (SDM) approach in Opioid Treatment Programs (OTPs) for the treatment of opioid use disorder. The objective is to adapt and test the impact of Implementation Facilitation (IF), a bundle of preparation, implementation, and sustainment strategies, on supporting...

The federal Project Grant award with ID DP2DA062283 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,542,500 grant, awarded on September 1, 2024, will support the development of novel econometric methods and a unified framework for integrating real-world evidence (RWE) to analyze inconclusive randomized controlled trials (RCTs) focused on opioid use disorder (OUD) treatments. The project, to be conducted by Weill...

The National Institute on Drug Abuse (NIDA) awarded a $220,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Amalgent Therapeutics, Inc. in Greenville, NC. This grant supports the development of a novel opioid adjuvant technology that aims to enhance the pain-relieving efficacy of opioid medications while mitigating risks such as abuse potential, tolerance, and neuropathic pain. The project has two key objectives: 1) investigating the mechanism by which the...

The Department of Justice, Office of Justice Programs, Bureau of Justice Assistance awarded a $1,600,000 Comprehensive Opioid, Stimulant, and other Substances Use Program (CFDA 16.838) Project Grant to the Southern Nevada Health District (SNHD) and sub-recipients Las Vegas Metropolitan Police Department (LVMPD) and University of Nevada, Las Vegas (UNLV). The grant will fund a collaborative initiative to address the opioid crisis in Clark County, Nevada through a public health-focused overdose...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to develop and evaluate an adaptive psychological intervention to improve pain management and reduce opioid use following an injury. The $264,995 grant, awarded on September 15, 2025, will fund the optimization and feasibility testing of a two-part intervention. The first part is a 15-minute computerized brief intervention focused on...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, will evaluate the benefits of a hand-held, automated, personalized oral liquid dispensing system for take-home methadone medication management for patients with opioid use disorder (OUD). The $326,410 award, with a performance period from June 1, 2025 to May 31, 2026, will support a clinical program delivered by Berkshire Biomedical Corporation. The project aims to...

This federal Project Grant award, titled "Dynamic Treatment Regimes for Personalized Opioid Use Disorder Care," was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $199,800 award supports the research efforts of Dr. Jason Brian Gibbons, an Assistant Professor at the University of Colorado Anschutz Medical Campus, over a 5-year period from August 2025 to July 2030. The overarching objective of the project is...

This federal Project Grant award of $459,045, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a study titled "The Cascade of Care for Patients with Opioid Use Disorder Identified Through a Large Public Health System." The study aims to modify the existing Opioid Use Disorder (OUD) Cascade of Care model to better reflect the changing landscape of real-world OUD treatment, enabling critical research...

This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...

This $424,545 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support a national survey on naloxone use and access. The survey, conducted by the RAND Corporation, will provide critical, timely evidence on the state of naloxone carrying and purchasing behavior in the U.S., including the impact of recently approved over-the-counter naloxone products. The project will monitor knowledge, barriers, and willingness-to-pay...